Bullish price channel on ABBV:The Stock is trading in the bullish price channel.
The price is near the support line so the probability is it will move up-to 95.92 to its support level.
Below 94.25 price can be bearish.
ABBV34 trade ideas
Breakout: 98V bottom but I am in as the stock has broken the prior high and I am hoping this is just a small pullback. Stock pays a fantastic dividend and I think biotech is a winner right now!
Breakout V Bottom: 98
Stop: under 84
Target 1: 120 to 126
Target 2: 143 to 155
ABBV potential consolidation or uptrend potential break thru resistance on the uptrend
or
potential consolidation after hitting resistance
ABBV both optionspotential break thru resistance on the uptrend
or
potential consolidation after hitting resistance
ABBV enters a monthly bullish trend. Expect Uptrend continuationA buy signal is generated. ABBV is predicted to grow by 4% to $99.9 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended up during the month, the odds of an Uptrend continuation are 89%.
FDA Approves JUVÉDERM® VOLUMA(TM) XC for Enhancement of the ChinABBV: AbbVie
2020-06-15 08:15:00
FDA Approves JUVÉDERM® VOLUMA(TM) XC for Enhancement of the Chin Region
$ABBV On breakout watch above $100P/E ratio 17.15
Company profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
ABBV: Buy at $85Great fundamentals and ratios
- recently broke the key level at $85.
- A pullback to $85 would be a great buy
targets:
$105
$125
ABBV Analysis Double Bottom Eve&Adam + EMA Cross + Bullish Time Frame Confluence + Bullish Momentum + Long Wick Rejections of Dynamic Support
Price Target: 97.86, 107.25, 113.59
Options Trade: 6/19 100c (Risky), 7/17 110c
ABBV an Entry Point into the Wild World of BiotechBiotechnology and pharmaceutical companies have been quickly cycling through overbought and oversold. The problem has been so problematic that Sorrento Therapeutics had to specifically claim they were not a “pump and dump” scheme. Any whisper of a "cure" for Covid-19 has investors rushing to the entrance and quickly fleeing after results are what they had expected (an image of people rushing toward the exit and getting stuck in door comes to my mind). People who know the biotech sector have been cautiously watching the spectacle and trying to avoid getting trampled in a stampede. To be clear: your average investor is getting burned in the vaccine-hunt game.
AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure.
From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern.
LONG ABBV purchased today (06-02-2020) @ 90.86.
